Dr. Têtu is professor emeritus at the Faculty of Medicine of Laval University and a regular researcher in the Oncology axis of the CHU Research Centre of Quebec since 1986. Since the beginning of his career, in addition to his clinical practice and research activities, particularly as a FRSQ senior clinical researcher grant holder, he held various executive positions such as head of the Division of Pathology in the Department of Molecular Biology, Medical Biochemistry and Pathology, Director of the Clinician-Scientist Residency Program and Graduate Program in Clinical Epidemiology, Medical Director of RUIS Telepathology Project at Laval University, Chief of Pathology Services at CHUQ and CHA, Assistant Director of Clinical Research at CHUQ Research Centre, Chair of the Advisory Committee on Anatomical Pathology at the Quebec Cancer Board (Ministry of Health) and Chair of the membership committee of the Canadian Association of Pathologists.
His research themes are:
Clinical validation of new tumor markers
His studies aim to validate tumor markers identified as potentially interesting for predicting the evolution of cancers. These studies are applied to cohorts of patients using histopathological approaches, and therefore involve expertise in cellular and molecular biology, pathology and epidemiology. Several studies use samples from a tumor bank that he has been developing for over 20 years.
Studying the benefits and challenges of using telepathology
Telepathology is a technology that Dr. Têtu has helped to introduce in eastern Quebec, and allows the pathologist to establish remote diagnostics, mainly in oncology. Collaborations with experts in information technology assessment, applied in telemedicine, help identify the socio-political, organizational, clinical, professional, legal and technological benefits and challenges related to the introduction of telepathology.
1050, chemin Sainte-Foy
Service d'anatomopathologie et de cytologie
Canada G1S 4L8
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.Journal Article
Cell, 173 (2), pp. 386-399.e12, 2018, ISSN: 0092-8674.
Comprehensive Characterization of Cancer Driver Genes and Mutations.Journal Article
Cell, 173 (2), pp. 371-385.e18, 2018, ISSN: 0092-8674.
Pathogenic Germline Variants in 10,389 Adult Cancers.Journal Article
Cell, 173 (2), pp. 355-370.e14, 2018, ISSN: 0092-8674.
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.Journal Article
Cell, 173 (2), pp. 338-354.e15, 2018, ISSN: 0092-8674.
Oncogenic Signaling Pathways in The Cancer Genome Atlas.Journal Article
Cell, 173 (2), pp. 321-337.e10, 2018, ISSN: 0092-8674.
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.Journal Article
Cell, 173 (2), pp. 305-320.e10, 2018, ISSN: 0092-8674.
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.Journal Article
Cell, 173 (2), pp. 291-304.e6, 2018, ISSN: 0092-8674.
Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.Journal Article
Cell Rep, 23 (1), pp. 172-180.e3, 2018.
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.Journal Article
Cell Rep, 23 (1), pp. 181-193.e7, 2018.
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.Journal Article
Cell Rep, 23 (1), pp. 194-212.e6, 2018.